Diagnosis and Prognosis of Sepsis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Sepsis is a physiological response to a source of infection that triggers mechanisms that compromise organ function, leading to death if not treated early. Biomarkers with high sensitivity, specificity, speed, and accuracy that could differentiate sepsis from non-infectious systemic inflammatory response syndrome (SIRS) could bring about a revolution in sepsis treatment. Given the limitations and time required for microbial verification of pathogens, the accurate diagnosis of infection before employing antibiotic therapy is important and clinically necessary. Procalcitonin (PCT), lactate, C-reactive protein (CRP), cytokines, and proadrenomedullin (ProADM) are the common biomarkers used for diagnosis. The procalcitonin (PCT)-guided antibiotic treatment in patients with acute respiratory infections effectively reduces antibiotic exposure and side effects while improving survival rates. The evidence regarding sepsis screening in hospitalized patients is limited. Clinicians, researchers, and healthcare decision-makers should consider these findings and limitations when implementing screening tools, future research, or policy on sepsis recognition in hospitalized patients. The use of biomarkers in pediatric sepsis is promising, although such use should always be correlated with clinical evaluation. Biomarkers may also improve the prediction of mortality, especially in the early phase of sepsis, when the levels of certain pro-inflammatory cytokines and proteins are elevated.
Abstract
Sepsis is a physiological response to a source of infection that triggers mechanisms that compromise organ function, leading to death if not treated early. Biomarkers with high sensitivity, specificity, speed, and accuracy that could differentiate sepsis from non-infectious systemic inflammatory response syndrome (SIRS) could bring about a revolution in sepsis treatment. Given the limitations and time required for microbial verification of pathogens, the accurate diagnosis of infection before employing antibiotic therapy is important and clinically necessary. Procalcitonin (PCT), lactate, C-reactive protein (CRP), cytokines, and proadrenomedullin (ProADM) are the common biomarkers used for diagnosis. The procalcitonin (PCT)-guided antibiotic treatment in patients with acute respiratory infections effectively reduces antibiotic exposure and side effects while improving survival rates. The evidence regarding sepsis screening in hospitalized patients is limited. Clinicians, researchers, and healthcare decision-makers should consider these findings and limitations when implementing screening tools, future research, or policy on sepsis recognition in hospitalized patients. The use of biomarkers in pediatric sepsis is promising, although such use should always be correlated with clinical evaluation. Biomarkers may also improve the prediction of mortality, especially in the early phase of sepsis, when the levels of certain pro-inflammatory cytokines and proteins are elevated.
참고문헌 (40)
- Angus DC, "Epidemiology of severe sepsis in the United States : analysis of incidence, outcome, and associated costs of care", Crit Care Med, 29, pp.1303~1310 (2001)[DOI]
- Lawrence KL, "Antimicrobial stewardship in the intensive care unit : advances and obstacles", Am J Respir Crit Care Med, 179, pp.434~438 (2009)[DOI]
- Kutz A, "Prognostic value of procalcitonin in respiratory tract infections across clinical settings", Crit Care, 19, pp.74~ (2015)[DOI]
- Schuetz P, "Serial procalcitonin predicts mortality in severe sepsis patients : results from the multicenter procalcitonin monitoring sepsis(MOSES)study", Crit Care Med, 45, pp.781~789 (2017)[DOI]
- Seymour CW, "Assessment of clinical criteria for sepsis : for the third international consensus definitions for sepsis and septic shock(Sepsis-3)", JAMA, 315, pp.762~774 (2016)[DOI]
- Kitanovski L, "Diagnostic accuracy of lipopolysaccharide-binding protein for predicting bacteremia", clinical sepsis in children with febrile neutropenia : comparison with interleukin-6, procalcitonin and C-reactive protein, 2014, pp.22, 269~277
- Amland RC, "Clinical decision support for early recognition of sepsis", Am J Med Qual, 31, pp.103~110 (2016)[DOI]
- Gyang E, "A nurse-driven screening tool for the early identification of sepsis in an intermediate care unit setting", J Hosp Med, 10, pp.97~103 (2015)[DOI]
- Schuetz P, "Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis", Lancet Infect Dis, 18, pp.95~107 (2018)[DOI]
- Levy MM, "Surviving sepsis campaign: association between performance metrics and outcomes in a 7.5-year study", Crit Care Med, 43, pp.3~12 (2015)[DOI]
- Dellinger RP, "Surviving sepsis campaign : international guidelines for management of severe sepsis and septic shock : 2012", Crit Care Med, 41, pp.580~637 (2013)[DOI]
- Liu S, "Clinical values of the early detection of serum procalcitonin, C-reactive protein and white blood cells for neonates with infectious diseases", Pak J Med Sci, 32, pp.1326~1329 (2016)[DOI]
- Pedro Póvoa, "Early identification of intensive care unit-acquired infections with daily monitoring of c-reactive protein: a prospective observational study", Critical Care, 10(2), pp.R63~ (2006), Springer Science and Business Media LLC[DOI]
- Kellum JA, "Understanding the inflammatory cytokine response in pneumonia and sepsis : results of the genetic and inflammatory markers of sepsis(GenIMS)study", Arch Intern Med, 167, pp.1655~1663 (2007)[DOI]
- Calfee CS, "Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock", Crit Care Med, 38, pp.1436~1441 (2010)[DOI]
- Prucha M, "Sepsis biomarkers", Clin Chim Acta, 440, pp.97~103 (2015)[DOI]
- P Schuetz, "Biomarker-guided personalised emergency medicine for all – hope for another hype?", Swiss Medical Weekly, 145, pp.w14079~ (2015), EMH Swiss Medical Publishers, Ltd.[DOI]
- Kelly BJ, "Combined biomarkers discriminate a low likelihood of bacterial infection among surgical intensive care unit patients with suspected sepsis", Diagn Microbiol Infect Dis, 85, pp.109~115 (2016)[DOI]
- Shapiro NI, "A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis", Crit Care Med, 37, pp.96~104 (2009)[DOI]
- Andersen LW, "Etiology and therapeutic approach to elevated lactate levels", Mayo Clin Proc, 88, pp.1127~1140 (2013)[DOI]
- Wong HR, "The pediatric sepsis biomarker risk model", Crit Care, 16, pp.R174~ (2012)[DOI]
- Singer M, "The third international consensus definitions for sepsis and septic shock(sepsis-3)", JAMA, 315, pp.801~810 (2016)[DOI]
- Weber GF, "Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis", Science, 347, pp.1260~1265 (2015)[DOI]
- O’Callaghan DJ, "Monocyte tumor necrosis factor-alpha-converting enzyme catalytic activity and substrate shedding in sepsis and noninfectious systemic inflammation", Crit Care Med, 43, pp.1375~1385 (2015)[DOI]
- Christine B. Read, "Cutting Edge: Identification of Neutrophil PGLYRP1 as a Ligand for TREM-1", The Journal of Immunology, 194(4), pp.1417~1421 (2015), The American Association of Immunologists[DOI]
- Motal MC, "Increased plasma vaspin concentration in patients with sepsis : an exploratory examination", Biochem Med(Zagreb), 25, pp.90~96 (2015)[DOI]
- Wang K, "Angiopoietin-1, angiopoietin-2 and bicarbonate as diagnostic biomarkers in children with severe sepsis", PLoS One, 9, pp.e108461~ (2014)[DOI]
- Benz F, "Circulating microRNAs as biomarkers for sepsis", Int J Mol Sci, 17, pp.78~ (2016)[DOI]
- Sanni Kumar, "Recent advances in biosensors for diagnosis and detection of sepsis: A comprehensive review", Biosensors and Bioelectronics, 124-125, pp.205~215 (2019), Elsevier BV[DOI]
- Stryjewski GR, "Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children", Pediatric Crit Care Med, 6, pp.129~135 (2005)[DOI]
- Bozza FA, "Cytokine profiles as markers of disease severity in sepsis : a multiplex analysis", Crit Care, 11, pp.R49~ (2007)[DOI]
- Tsujimoto H, "Neutrophil elastase, MIP-2, and TLR-4 expression during human and experimental sepsis", Shock, 23, pp.39~44 (2005)[DOI]
- Vaschetto R, "Serum levels of osteopontin are increased in SIRS and sepsis", Intensive Care Med, 34, pp.2176~2184 (2008)[DOI]
- Mikolajczyk TP, "Role of chemokine RANTES in the regulation of perivascular inflammation, T-cell accumulation, and vascular dysfunction in hypertension", FASEB J., 30, pp.1987~1999 (2016)[DOI]
- Wright SW, "sTREM-1 predicts mortality in hospitalized patients with infection in a tropical, middle-income country", BMC Med, 18, pp.159~ (2020)[DOI]
- Behnes M, "Diagnostic and prognostic utility of soluble CD 14 subtype(presepsin)for severe sepsis and septic shock during the first week of intensive care treatment", Crit Care, 18, pp.507~ (2014)[DOI]
- Mansur A, "The regulatory toll-like receptor 4 genetic polymorphism rs11536889 is associated with renal, coagulation and hepatic organ failure in sepsis patients", J Transl Med, 12, pp.177~ (2014)[DOI]
- Sinha M, "Emerging technologies for molecular diagnosis of sepsis", Clin Microbiol Rev, 31, pp.e00089~ (2018)[DOI]
- Bloos F, "Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock : a randomized clinical trial", JAMA Intern Med, 176, pp.1266~1276 (2016)[DOI]
- Vincent JL, "Sepsis in European intensive care units : results of the SOAP study", Crit Care Med, 34, pp.344~353 (2006)[DOI]